hit counter
Celcuity Inc. (CELC) Stock News Sentiment & Price - Sentifly
CELC - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Celcuity Inc. (CELC)

USA
Medical Laboratories & Research
NASDAQ
CELC Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CELC Latest news
Accesswire
Neutral
Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences
2021-11-09 17:30

MINNEAPOLIS, MN / ACCESSWIRE / November 9, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in virtual meetings with investors at the following conferences: 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021; and Jefferies London Healthcare Conference on November 18 - 19, 2021. About Celcuity Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy.

Seeking Alpha
Neutral
Celcuity Inc. (CELC) CEO Brian Sullivan on Q3 2021 Results - Earnings Call Transcript
2021-11-08 22:14

Celcuity Inc. (CELC) CEO Brian Sullivan on Q3 2021 Results - Earnings Call Transcript

Accesswire
Neutral
Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
2021-11-08 16:00

On track to obtain FDA feedback and initiate a Phase 3 study for gedatolisib during the first half of 2022 Will present updated Phase 1b data during a Spotlight Poster Discussion Session at the 2021 San Antonio Breast Cancer Symposium in December 2021 Entered into clinical trial collaboration with University of Rochester Wilmot Cancer Center and Puma Biotechnology to evaluate new therapeutic option for metastatic breast cancer patients with brain metastases Management to host webcast and conference call today, November 8, 2021, at 4:30 p.m. ET / 1:30 p.m.

Accesswire
Neutral
Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call
2021-10-29 09:00

MINNEAPOLIS, MN / ACCESSWIRE / October 29, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced that it will release its financial results for the third quarter 2021 after the stock market close on Monday, November 8, 2021. Management will host a webcast/teleconference the same day at 4:30 p.m.

Business Wire
Neutral
Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases
2021-10-18 16:09

MINNEAPOLIS--(BUSINESS WIRE)---- $CELC #Celcuity--Celcuity announces clinical trial collaboration with U of Rochester and Puma for Phase 2 breast cancer study. Patient selection guided by CELsignia.

Pulse2
Neutral
CELC Stock: $50 Price Target From Canaccord
2021-10-11 21:23

The shares of Celcuity Inc (NASDAQ: CELC) have received a price target of $50. These are the details.

Accesswire
Neutral
Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
2021-08-09 16:00

Raised approximately $56.3 million of gross proceeds from a follow-on public offering of common stock in early July to provide funding for clinical development activities  After follow-on offering, Celcuity had approximately $94.4 million of cash on hand  Expanded clinical development and clinical operations capabilities with appointment of two new senior executives and the addition of other key team members  In a Phase 1 study evaluating gedatolisib combined with paclitaxel and carboplatin, 65% of patients (11/17) had an objective response, including three complete responses  Management to host webcast and conference call today, August 9, 2021, at 4:30 p.m. ET / 1:30 p.m.

Accesswire
Neutral
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference
2021-08-05 08:00

MINNEAPOLIS, MN / ACCESSWIRE / August 5, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced its participation in the Canaccord Genuity 41st Annual Growth Conference to be held August 10-12, 2021. Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, is scheduled to present in a virtual fireside chat at 8:30 a.m.

Accesswire
Neutral
Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast
2021-08-02 07:30

MINNEAPOLIS, MN / ACCESSWIRE / August 2, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treating patients with cancer, today announced that it will release its financial results for the second quarter 2021 after the stock market close on Monday, August 9, 2021. Management will host a teleconference the same day at 4:30 p.m.

Accesswire
Neutral
Celcuity to Participate in the William Blair Biotech Focus Conference
2021-07-08 16:15

MINNEAPOLIS, MN / ACCESSWIRE / July 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced its participation in the William Blair Biotech Focus Conference to be held July 14-15, 2021. Brian Sullivan, Chairman, Chief Executive Officer, and Co-Founder of Celcuity, is scheduled to present in a fireside chat at 2 p.m.

Loading more news...